

Title (en)

Pharmaceutical composition of olmesartan medoxomil

Title (de)

Pharmazeutische Zusammensetzung mit Olmesartan-Medoxomil

Title (fr)

Composition pharmaceutique d'olmésartan médoxomil

Publication

EP 1891952 A1 20080227 (EN)

Application

EP 06009223 A 20060504

Priority

EP 06009223 A 20060504

Abstract (en)

A stable formulation of olmesartan medoxomil is prepared, exhibiting exceptional stability when subjected to stress conditions.

IPC 8 full level

A61K 31/4178 (2006.01); **A61K 9/20** (2006.01); **A61K 9/28** (2006.01)

CPC (source: EP US)

A61K 9/2013 (2013.01 - EP US); **A61K 31/4178** (2013.01 - EP US); **A61K 9/2018** (2013.01 - EP US); **A61K 9/2054** (2013.01 - EP US); **A61K 9/2866** (2013.01 - EP US)

Citation (search report)

- [X] EP 1604664 A1 20051214 - SANKYO CO [JP]
- [X] WO 2005042022 A2 20050512 - PFIZER LTD [GB], et al
- [X] WO 2006029057 A1 20060316 - TEVA PHARMA [IL], et al
- [X] WO 2006000564 A1 20060105 - SOLVAY PHARM GMBH [DE], et al
- [A] LV ALLEN: "Stearic Acid (in: Handbook of Pharmaceutical Excipients)", 9 August 2005, APHA PHARMACEUTICAL PRESS, LONDON, CHICAGO, XP002404582

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK YU

DOCDB simple family (publication)

WO 2007128478 A2 20071115; **WO 2007128478 A3 20080207**; AT E526963 T1 20111015; CA 2651138 A1 20071115; CA 2651138 C 20160216; EP 1891952 A1 20080227; EP 1891952 B1 20111005; EP 2021002 A2 20090211; EP 2021002 B1 20120530; ES 2388880 T3 20121019; PL 2021002 T3 20121130; SI 1891952 T1 20120229; SI 2021002 T1 20121030; US 2009238871 A1 20090924; US 9707178 B2 20170718

DOCDB simple family (application)

EP 2007003868 W 20070502; AT 06009223 T 20060504; CA 2651138 A 20070502; EP 06009223 A 20060504; EP 07724794 A 20070502; ES 07724794 T 20070502; PL 07724794 T 20070502; SI 200631227 T 20060504; SI 200731003 T 20070502; US 29923707 A 20070502